RecruitingPhase 1NCT06842186
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
Sponsor
Wave Life Sciences Ltd.
Enrollment
136 participants
Start Date
Jan 31, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria3
- Male and female participants aged 18 to 60 years
- BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records)
- Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments
Exclusion Criteria5
- History or presence of CV disease, including heart failure (New York Heart Association \[NYHA\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments
- History or presence of thyroid disorders
- Medical history or diagnosis of causes of liver disease
- Use of any siRNA agent in the prior 12 months
- Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGWVE-007
Stereopure siRNA oligonucleotide
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06842186
Related Trials
"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"
NCT068579291 location
CHIME: Comparing Health Interventions for Maternal Equity
NCT067241724 locations
Advancing Biopsychosocial Care Training Initiative
NCT070498611 location
A Mobile Intervention to Reduce Pain and Improve Health-III
NCT066236691 location
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT073118505 locations